Nektar Therapeutics
NKTR
389 hedge funds and large institutions have $9.73B invested in Nektar Therapeutics in 2018 Q3 according to their latest regulatory filings, with 55 funds opening new positions, 178 increasing their positions, 107 reducing their positions, and 41 closing their positions.
66% more repeat investments, than reductions
Existing positions increased: 178 | Existing positions reduced: 107
45% more call options, than puts
Call options by funds: $225M | Put options by funds: $155M
34% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 41
24% more capital invested
Capital invested by funds: $7.83B → $9.73B (+$1.9B)
3% more funds holding
Funds holding: 379 → 389 (+10)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
0.07% less ownership
Funds ownership: 6.24% → 6.17% (-0.07%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$75.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$50.3M |
| 3 |
Capital Fund Management (CFM)
Paris,
France
|
+$40.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$37.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$34.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$102M |
| 2 |
Primecap Management
Pasadena,
California
|
-$42.6M |
| 3 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
-$39.8M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$39.3M |
| 5 |
Millennium Management
New York
|
-$35.3M |
NKTR Hedge Fund Activity: Q3 2018 in Review
389 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2018, worth a combined $9.73B — up 24% from $7.83B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new NKTR positions and 41 closed out — a net gain of 14 holders — while 178 added to existing stakes and 107 trimmed.
The largest buyer was First Trust Advisors, adding an estimated $75.1M. The largest seller was Fidelity Investments, cutting an estimated $102M.
- 389 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2018, up from 379 in Q2 2018.
- Funds reported $9.73B of Nektar Therapeutics stock for Q3 2018, up 24% quarter-over-quarter.
- 55 funds opened new Nektar Therapeutics positions in Q3 2018 and 41 closed out, a net change of +14 holders.
- The largest Nektar Therapeutics buyer in Q3 2018 was First Trust Advisors, an estimated $75.1M added.
- The largest Nektar Therapeutics seller in Q3 2018 was Fidelity Investments, an estimated $102M sold.
Based on aggregated 13F filings for Q3 2018.